Logo Logo
Switch Language to German

Kretschmer, Alexander; Mazzone, Elio; Barletta, Francesco; Leni, Riccardo; Heidegger, Isabel; Tsaur, Igor; Bergh, Roderick C. N. van den; Valerio, Massimo; Marra, Giancarlo; Kasivisvanathan, Veeru; Buchner, Alexander; Stief, Christian G.; Briganti, Alberto; Montorsi, Francesco; Tilki, Derya and Gandaglia, Giorgio (2021): Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. In: European Urology Focus, Vol. 7, No. 6: pp. 1247-1253

Full text not available from 'Open Access LMU'.


Background: Although an increasing number of prostate cancer (PCa) patients received holmium laser enucleation of the prostate (HoLEP) previously for benign prostatic obstruction (BPO), there is still no evidence regarding the outcomes of radical prostatectomy (RP) in this setting. Objective: To assess functional and oncological results of RP in PCa patients who received HoLEP for BPO previously in a contemporary multi-institutional cohort. Design, setting, and participants: A total of 95 patients who underwent RP between 2011 and 2019 and had a history of HoLEP were identified in two institutions. Functional as well as oncological follow-up was prospectively assessed and retrospectively analyzed. Intervention: RP following HoLEP compared with RP without previous transurethral surgery. Outcome measurements and statistical analysis: Patients with complete follow-up data were matched with individuals with no history of BPO surgery using propensity score matching. Complications were assessed using the Clavien-Dindo scale. Results and limitations: The median follow-up was 50.5 mo. We found no significant impact of previous HoLEP on positive surgical margin rate (14.0% [HoLEP] vs 18.8% [no HoLEP], p = 0.06) and biochemical recurrence-free survival (hazard ratio 0.74, 95% confidence interval [CI] 0.32-1.70, p = 0.4). Patients with a history of HoLEP had increased 1-yr urinary incontinence rates after RP. After adjusting for confounders, no significant impact of previous HoLEP was found (odds ratio [OR] 0.87, 95% CI 0.74-1.01;p = 0.07). Previous HoLEP did not hamper 1-yr erectile function recovery (OR 1.22, 95% CI 1.05-1.43;p = 0.01). Limitations include retrospective design and small sample size.

Actions (login required)

View Item View Item